Influenza A(H7N9) virus acquires resistance-related neuraminidase I222T substitution when infected mallards are exposed to low levels of oseltamivir in water

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 9, 2015, Pages 5196-5202

  Gillman, Anna ^a   Nykvist, Marie ^a   Muradrasoli, Shaman ^a,b   Söderström, Hanna ^c   Wille, Michelle ^d   Daggfeldt, Annika ^e   Bröjer, Caroline ^e   Waldenström, Jonas ^d   Olsen, Björn ^a   Järhult, Josef D ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES   (Sweden)

^c UMEÅ UNIVERSITY   (Sweden)

^d LINNAEUS UNIVERSITY   (Sweden)

^e Swedish Veterinary Institute   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

4 ACETAMIDO 5 AMINO 3 (1 ETHYLPROPOXY) 1 CYCLOHEXENE 1 CARBOXYLIC ACID; VIRUS RNA; VIRUS SIALIDASE; WATER; ZANAMIVIR; OSELTAMIVIR; SIALIDASE;

AMINO ACID SUBSTITUTION; ANAS PLATYRHYNCHOS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; FECES; GENOTYPE; IC50; INFLUENZA A; INFLUENZA A VIRUS (H7N9); MALE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; VIRUS DETECTION; VIRUS EXCRETION; VIRUS RESISTANCE; ANALOGS AND DERIVATIVES; ANIMAL; CHEMISTRY; DRUG EFFECTS; DUCK; ENZYMOLOGY; GENETICS; METABOLISM;

ANIMALS; DUCKS; INFLUENZA A VIRUS, H7N9 SUBTYPE; NEURAMINIDASE; OSELTAMIVIR; WATER;

EID: 84940936073     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00886-15     Document Type: Article

References (63)

1. Webster RG, Bean WJ, Gorman O.T., Chambers TM, Kawaoka Y. 1992. Evolution and ecology of influenza A viruses. Microbiol Rev 56:152-179.
2. Jourdain E, Gunnarsson G, Wahlgren J., Latorre-Margalef N, Bröjer C, Sahlin S., Svensson L, Waldenström J, Lundkvist Å Olsen B. 2010. Influenza virus in a natural host, the mallard: experimental infection data. PLoS One 5:e8935. http://dx.doi.org/10.1371/journal.pone.0008935.
3. Latorre-Margalef N., Gunnarsson G, Munster V.J., Fouchier RA, Osterhaus AD, Elmberg J, Olsen B., Wallensten A, Haemig PD, Fransson T, Brudin L., Waldenström J. 2009. Effects of influenza A virus infection on migrating mallard ducks. Proc Biol Sci 276:1029-1036. http://dx.doi.org/10.1098/rspb.2008.1501.
4. Dugan VG, Chen R, Spiro D.J., Sengamalay N., Zaborsky J, Ghedin E, Nolting J., Swayne DE, Runstadler JA, Happ GM, Senne D.A., Wang R., Slemons RD, Holmes EC, Taubenberger JK. 2008. The evolutionary genetics and emergence of avian influenza viruses in wild birds. PLoS Pathog 4:e1000076. http://dx.doi.org/10.1371/journal.ppat.1000076.
5. Olsen B, Munster VJ, Wallensten A, Waldenström J, Osterhaus A.D., Fouchier RA. 2006. Global patterns of influenza A virus in wild birds. Science 312:384-388. http://dx.doi.org/10.1126/science.1122438.
6. Guan Y, Vijaykrishna D, Bahl J., Zhu H, Wang J, Smith GJ 2010. The emergence of pandemic influenza viruses. Protein Cell 1:9-13. http://dx.doi.org/10.1007/s13238-010-0008-z.
7. Liu D, Shi W, Shi Y., Wang D, Xiao H, Li W., Bi Y, Wu Y, Li X., Yan J, Liu W, Zhao G., Yang W, Wang Y, Ma J., Shu Y, Lei F, Gao GF. 2013. Origin and diversity of novel avian influenza A H7N9 viruses causing human infection: phylogenetic, structural, and coalescent analyses. Lancet 381:1926-1932. http://dx.doi.org/10.1016/S0140-6736(13)60938-1.
8. Forrest HL, Webster RG 2010. Perspectives on influenza evolution and the role of research. Anim Health Res Rev 11:3-18. http://dx.doi.org/10.1017/S1466252310000071.
9. Jernigan DB, Cox NJ 2015. H7N9: preparing for the unexpected in influenza. Annu Rev Med 66:361-371. http://dx.doi.org/10.1146/annurev-med-010714-112311.
10. Lam TT, Wang J, Shen Y., Zhou B, Duan L, Cheung C.L., Ma C., Lycett SJ, Leung CY, Chen X, Li L., Hong W, Chai Y, Zhou L., Liang H, Ou Z, Liu Y., Farooqui A, Kelvin DJ, Poon LL, Smith DK, Pybus OG, Leung GM, Shu Y, Webster RG, Webby RJ, Peiris JS, Rambaut A, Zhu H, Guan Y. 2013. The genesis and source of the H7N9 influenza viruses causing human infections in China. Nature 502:241-244. http://dx.doi.org/10.1038/nature12515.
11. Watanabe T, Kiso M, Fukuyama S., Nakajima N, Imai M, Yamada S., Murakami S, Yamayoshi S, Iwatsuki-Horimoto K, Sakoda Y., Takashita E, McBride R, Noda T., Hatta M, Imai H, Zhao D., Kishida N, Shirakura M, de Vries RP, Shichinohe S, Okamatsu M, Tamura T, Tomita Y, Fujimoto N, Goto K, Katsura H, Kawakami E, Ishikawa I, Watanabe S, Ito M, Sakai-Tagawa Y, Sugita Y, Uraki R, Yamaji R, Eisfeld AJ, Zhong G, Fan S, Ping J, Maher EA, Hanson A, Uchida Y, Saito T, Ozawa M, Neumann G, Kida H, Odagiri T, Paulson JC, Hasegawa H, Tashiro M, Kawaoka Y. 2013. Characterization of H7N9 influenza A viruses isolated from humans. Nature 501:551-555. http://dx.doi.org/10.1038/nature12392.
12. Lam TT, Zhou B, Wang J., Chai Y, Shen Y, Chen X., Ma C, Hong W, Chen Y., Zhang Y, Duan L, Chen P., Jiang J, Zhang Y, Li L., Poon LL, Webby RJ, Smith DK, Leung GM, Peiris JS, Holmes EC, Guan Y, Zhu H. 2015. Dissemination, divergence and establishment of H7N9 influenza viruses in China Nature 522:102-105. http://dx.doi.org/10.1038/nature14348.
13. World Health Organization. 2015. Human infection with avian influenza A(H7N9) virus - China. Disease outbreak news 11 March 2015. http://www.who.int/csr/don/11-march-2015-avian-influenza-china/en/.
14. Nguyen-Van-Tam JS, Openshaw PJ, Nicholson KG. 2014. Antivirals for influenza: where now for clinical practice and pandemic preparedness? Lancet 384:386-387. http://dx.doi.org/10.1016/S0140-6736(14)60726-1.
15. Webster RG, Govorkova EA 2014. Continuing challenges in influenza. AnnN Y Acad Sci 1323:115-139. http://dx.doi.org/10.1111/nyas.12462.
16. Patel A, Gorman SE 2009. Stockpiling antiviral drugs for the next influenza pandemic. Clin Pharmacol Ther 86:241-243. http://dx.doi.org/10.1038/clpt.2009.142.
17. Wan Po A.L., Farndon P, Palmer N. 2009. Maximizing the value of drug stockpiles for pandemic influenza. Emerg Infect Dis 15:1686-1687. http://dx.doi.org/10.3201/eid1510.090844.
18. Baranovich T, Burnham AJ, Marathe B.M., Armstrong J., Guan Y, Shu Y, Peiris J.M., Webby RJ, Webster RG, Govorkova EA. 2014. The neuraminidase inhibitor oseltamivir is effective against A/Anhui/1/2013 (H7N9) influenza virus in a mouse model of acute respiratory distress syndrome. J Infect Dis 209:1343-1353. http://dx.doi.org/10.1093/infdis/jit554.
19. Hu Y, Lu S, Song Z., Wang W, Hao P, Li J., Zhang X, Yen HL, Shi B, Li T., Guan W, Xu L, Liu Y., Wang S, Zhang X, Tian D., Zhu Z, He J, Huang K, Chen H, Zheng L, Li X, Ping J, Kang B, Xi X, Zha L, Li Y, Zhang Z, Peiris M, Yuan Z. 2013. Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance. Lancet 381:2273-2279. http://dx.doi.org/10.1016/S0140-6736(13)61125-3.
20. Järhult JD. 2012. Oseltamivir (Tamiflu) in the environment, resistance development in influenza A viruses of dabbling ducks and the risk of transmissionofan oseltamivir-resistant virus tohumans - a review. Infect Ecol Epidemiol 2. http://dx.doi.org/10.3402/iee.v2i0.18385.
21. Fick J, Lindberg RH, Tysklind M, Haemig P.D., Waldenström J, Wallensten A., Olsen B. 2007. Antiviral oseltamivir is not removed or degraded in normal sewage water treatment: implications for development of resistance by influenza A virus. PLoS One 2:e986. http://dx.doi.org/10.1371/journal.pone.0000986.
22. Ghosh GC, Nakada N, Yamashita N., Tanaka H. 2010. Occurrence and fate of oseltamivir carboxylate (Tamiflu) and amantadine in sewage treatment plants. Chemosphere 81:13-17. http://dx.doi.org/10.1016/j.chemosphere.2010.07.023.
23. Bartels P, von Tumpling W, Jr. 2008. The environmental fate of the antiviral drug oseltamivir carboxylate in different waters. Sci Total Environ 405:215-225. http://dx.doi.org/10.1016/j.scitotenv.2008.06.032.
24. Söderström H, Järhult JD, Olsen B, Lindberg RH, Tanaka H, Fick J. 2009. Detection of the antiviral drug oseltamivir in aquatic environments. PLoS One 4:e6064. http://dx.doi.org/10.1371/journal.pone.0006064.
25. Takanami R, Ozaki H, Giri R.R., Taniguchi S., Hayashi S. 2010. Detection of antiviral drugs oseltamivir phosphate and oseltamivir carboxylate in Neya River, Osaka Japan. J Water Environ Technol 8:363-372. http://dx.doi.org/10.2965/jwet.2010.363.
26. Azuma T, Nakada N, Yamashita N., Tanaka H. 2012. Synchronous dynamics of observed and predicted values of anti-influenza drugs in environmental waters during a seasonal influenza outbreak. Environ Sci Technol 46:12873-12881. http://dx.doi.org/10.1021/es303203c.
27. Ghosh GC, Nakada N, Yamashita N., Tanaka H. 2010. Oseltamivir carboxylate, the active metabolite of oseltamivir phosphate (Tamiflu), detected in sewage discharge and river water in Japan. Environ Health Perspect 118:103-107. http://dx.doi.org/10.1289/ehp.0900930.
28. Prasse C, Schlusener MP, Schulz R, Ternes TA 2010. Antiviral drugs in wastewater and surface waters: a new pharmaceutical class of environmental relevance? Environ Sci Technol 44:1728-1735. http://dx.doi.org/10.1021/es903216p.
29. Gonçalves C., Perez S, Osorio V., Petrovic M, Alpendurada MF, Barcelo D. 2011. Photofate of oseltamivir (Tamiflu) and oseltamivir carboxylate under natural and simulated solar irradiation: kinetics, identification of the transformation products, and environmental occurrence. Environ Sci Technol 45:4307-4314. http://dx.doi.org/10.1021/es1032629.
30. Singer AC, Järhult JD, Grabic R., Khan GA, Lindberg RH, Fedorova G, Fick J., Bowes MJ, Olsen B, Söderstrom H. 2014. Intra- and interpandemic variations of antiviral, antibiotics and decongestants in waste-water treatment plants and receiving rivers. PLoS One 9:e108621. http://dx.doi.org/10.1371/journal.pone.0108621.
31. Gillman A, Muradrasoli S, Söderstrom H, Nordh J., Bröjer C, Lindberg R.H., Latorre-Margalef N, Waldenström J, Olsen B., Järhult JD. 2013. Resistance mutation R292K is induced in influenza A(H6N2) virus by exposure of infected mallards to low levels of oseltamivir. PLoS One 8:e71230. http://dx.doi.org/10.1371/journal.pone.0071230.
32. Järhult J.D., Muradrasoli S, Wahlgren J., Söderstrom H, Orozovic G., Gunnarsson G, Bröjer C, Latorre-Margalef N, Fick J, Grabic R., Lennerstrand J, Waldenström J, Lundkvist Å Olsen B. 2011. Environmental levels of the antiviral oseltamivir induce development of resistance mutation H274Y in influenza A/H1N1 virus in mallards. PLoS One 6:e24742. http://dx.doi.org/10.1371/journal.pone.0024742.
33. Achenbach JE, Bowen RA 2013. Effect of oseltamivir carboxylate consumption on emergence of drug-resistant H5N2 avian influenza virus in mallard ducks. Antimicrob Agents Chemother 57:2171-2181. http://dx.doi.org/10.1128/AAC.02126-12.
34. Gillman A, Muradrasoli S, Söderstrom H, Holmberg F., Latorre-Margalef N, Tolf C, Waldenström J, Gunnarsson G., Olsen B, Järhult JD. 2015. Oseltamivir-resistant influenza A (H1N1) virus strain with an H274Y mutation in neuraminidase persists without drug pressure in infected mallards. Appl Environ Microbiol 81:2378-2383. http://dx.doi.org/10.1128/AEM.04034-14.
35. Wallensten A, Munster VJ, Latorre-Margalef N, Brytting M., Elmberg J, Fouchier RA, Fransson T, Haemig P.D., Karlsson M., Lundkvist Å Osterhaus AD, Stervander M, Waldenström J, Olsen B. 2007. Surveillance of influenza A virus in migratory waterfowl in northern Europe. Emerg Infect Dis 13:404-411. http://dx.doi.org/10.3201/eid1303.061130.
36. Fouchier RAM, Munster V, Wallensten A., Bestebroer TM, Herfst S, Smith D, Rimmelzwaan G.F., Olsen B., Osterhaus ADME. 2005. Characterization of a novel influenza a virus hemagglutinin subtype (H16) obtained from black-headed gulls. J Virol 79:2814-2822. http://dx.doi.org/10.1128/JVI.79.5.2814-2822.2005.
37. Hoffmann E, Stech J, Guan Y., Webster RG, Perez DR. 2001. Universal primer set for the full-length amplification of all influenza A viruses. Arch Virol 146:2275-2289. http://dx.doi.org/10.1007/s007050170002.
38. Hurt A. 2007. Standard operating procedure WHO-025: Fluorometric neuraminidase inhibition assay. Official copy. World Health Organization Collaborating Centre for Reference & Research on Influenza Australia. http://www.nisn.org/documents/A.Hurt-Protocol-for-NA-fluorescence.pdf.
39. Bröjer C., Järhult JD, Muradrasoli S., Söderstrom H, Olsen B., Gavier-Widen D. 2013. Pathobiology and virus shedding of low-pathogenic avian influenza virus (A/H1N1) infection in mallards exposed to oseltamivir. J Wildl Dis 49:103-113. http://dx.doi.org/10.7589/2011-11-335.
40. Spackman E, Suarez DL 2008. Type A influenza virus detection and quantitation by real-time RT-PCR. Methods Mol Biol 436:19-26. http://dx.doi.org/10.1007/978-1-59745-279-3-4.
41. Potier M, Mameli L, Belisle M., Dallaire L, Melancon SB. 1979. Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-alpha-D-N-acetylneuraminate) substrate. Anal Biochem 94:287-296. http://dx.doi.org/10.1016/0003-2697(79)90362-2.
42. Lackenby A. 24 May 2008. Determination of influenza virus susceptibility to neuraminidase inhibitors using a fluorescent substrate, p 1-15. Neuraminidase Inhibitor Surveillance Network. http://www.nisn.org/documents/Zambon-VIRGIL-IC50-SOP.pdf.
43. Khan GA, Lindberg R, Grabic R., Fick J. 2012. The development and application ofasystem for simultaneously determining anti-infectives and nasal decongestants using on-line solid-phase extraction and liquid chromatography-tandem mass spectrometry. JPharm Biomed Anal 66:24-32. http://dx.doi.org/10.1016/j.jpba.2012.02.011.
44. Bao Y, Bolotov P, Dernovoy D., Kiryutin B, Zaslavsky L, Tatusova T., Ostell J, Lipman D. 2008. The influenza virus resource at the National Center for Biotechnology Information. J Virol 82:596-601. http://dx.doi.org/10.1128/JVI.02005-07.
45. Lebarbenchon C, Brown JD, Stallknecht DE 2013. Evolution of influenza A virus H7 and N9 subtypes, Eastern Asia. Emerg Infect Dis 19:1635-1638. http://dx.doi.org/10.3201/eid1910.130609.
46. Marjuki H, Mishin VP, Chesnokov A.P., Jones J., De La Cruz JA, Sleeman K, Tamura D, Nguyen HT, Wu HS, Chang FY, Liu MT, Fry AM, Cox NJ, Villanueva JM, Davis CT, Gubareva LV. 2015. Characterization of drug-resistant influenza A(H7N9) variants isolated from an oseltamivirtreated patient in Taiwan. J Infect Dis 211:249-257. http://dx.doi.org/10.1093/infdis/jiu447.
47. Pizzorno A, Abed Y, Plante P.L., Carbonneau J., Baz M, Hamelin ME, Corbeil J, Boivin G. 2014. Evolution of oseltamivir resistance mutations in influenza A(H1N1) and A(H3N2) viruses during selection in experimentally infected mice. Antimicrob Agents Chemother 58:6398-6405. http://dx.doi.org/10.1128/AAC.02956-14.
48. Varghese JN, McKimm-Breschkin JL, Caldwell J.B., Kortt AA, Colman PM. 1992. The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor. Proteins 14:327-332. http://dx.doi.org/10.1002/prot.340140302.
49. Sheu TG, Deyde VM, Okomo-Adhiambo M, Garten R.J., Xu X., Bright RA, Butler EN, Wallis TR, Klimov A.I., Gubareva LV. 2008. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother 52:3284-3292. http://dx.doi.org/10.1128/AAC.00555-08.
50. Hatakeyama S, Sugaya N, Ito M., Yamazaki M, Ichikawa M, Kimura K., Kiso M, Shimizu H, Kawakami C., Koike K, Mitamura K, Kawaoka Y. 2007. Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors. JAMA 297:1435-1442.
51. Lee HK, Tang JW, Loh T.P., Hurt AC, Oon LL, Koay ES. 2015. Molecular surveillance of antiviral drug resistance of influenza A/H3N2 virus in Singapore, 2009-2013. PLoS One 10:e0117822. http://dx.doi.org/10.1371/journal.pone.0117822.
52. Dapat C, Kondo H, Dapat I.C., Baranovich T., Suzuki Y, Shobugawa Y, Saito K., Saito R, Suzuki H. 2013. Neuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009-2010 and 2010-2011 influenza seasons in Japan. Antiviral Res 99:261-269. http://dx.doi.org/10.1016/j.antiviral.2013.06.003.
53. McKimm-Breschkin JL. 2012. Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance. Influenza Other Respir Viruses 7(Suppl 1):25-36. http://dx.doi.org/10.1111/irv.12047.
54. McKimm-Breschkin J.L., Barrett S, Pudjiatmoko Azhar M, Wong FY, Selleck P, Mohr P.G., McGrane J., Kim M. 2013. I222 neuraminidase mutations further reduce oseltamivir susceptibility of Indonesian clade 2.1 highly pathogenic avian influenza A(H5N1) viruses. PLoS One 8:e66105. http://dx.doi.org/10.1371/journal.pone.0066105.
55. van der Vries E, Collins PJ, Vachieri SG, Xiong X, Liu J, Walker PA, Haire LF, Hay AJ, Schutten M, Osterhaus AD, Martin SR, Boucher CA, Skehel JJ, Gamblin SJ. 2012. H1N1 2009 pandemic influenza virus: resistance of the I223R neuraminidase mutant explained by kinetic and structural analysis. PLoS Pathog 8:e1002914. http://dx.doi.org/10.1371/journal.ppat.1002914.
56. Huang L, Cao Y, Zhou J., Qin K, Zhu W, Zhu Y., Yang L, Wang D, Wei H., Shu Y. 2014. A conformational restriction in the influenza A virus neuraminidase binding site by R152 results in a combinational effect of I222T and H274Y on oseltamivir resistance. Antimicrob Agents Chemother 58:1639-1645. http://dx.doi.org/10.1128/AAC.01848-13.
57. Pizzorno A, Abed Y, Bouhy X., Beaulieu E, Mallett C, Russell R., Boivin G. 2012. Impact of mutations at residue I223 of the neuraminidase protein on the resistance profile, replication level, and virulence of the 2009 pandemic influenza virus. Antimicrob Agents Chemother 56:1208-1214. http://dx.doi.org/10.1128/AAC.05994-11.
58. Baz M, Abed Y, McDonald J., Boivin G. 2006. Characterization of multidrug-resistant influenza A/H3N2 viruses shed during 1 year by an immunocompromised child. Clin Infect Dis 43:1555-1561. http://dx.doi.org/10.1086/508777.
59. Simon P, Holder BP, Bouhy X, Abed Y., Beauchemin CA, Boivin G. 2011. The I222V neuraminidase mutation has a compensatory role in replication of an oseltamivir-resistant influenza virus A/H3N2 E119V mutant. J Clin Microbiol 49:715-717. http://dx.doi.org/10.1128/JCM.01732-10.
60. Duan S, Govorkova EA, Bahl J, Zaraket H., Baranovich T, Seiler P, Prevost K., Webster RG, Webby RJ. 2014. Epistatic interactions between neuraminidase mutations facilitated the emergence of the oseltamivir-resistant H1N1 influenza viruses. Nat Commun 5:5029. http://dx.doi.org/10.1038/ncomms6029.
61. Burnham AJ, Armstrong J, Lowen A.C., Webster RG, Govorkova EA. 2015. Competitive fitness of influenza B viruses with neuraminidase inhibitorresistant substitutions in a co-infection model of the human airway epithelium. J Virol 89:4575-4587. http://dx.doi.org/10.1128/JVI.02473-14.
62. Burnham AJ, Baranovich T, Marathe B.M., Armstrong J., Webster RG, Govorkova EA. 2014. Fitness costs for influenza B viruses carrying neuraminidase inhibitor-resistant substitutions: underscoring the importance of E119A and H274Y. Antimicrob Agents Chemother 58:2718-2730. http://dx.doi.org/10.1128/AAC.02628-13.
63. World Health Organization. 2012. Meetings of the WHO working group on surveillance of influenza antiviral susceptibility - Geneva, November 2011 and June 2012. Wkly Epidemiol Rec 87:369-374.